Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia
2009-11
Loading...
View/Download File
Persistent link to this item
Statistics
View StatisticsJournal Title
Journal ISSN
Volume Title
Title
Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia
Authors
Published Date
2009-11
Publisher
Type
Thesis or Dissertation
Abstract
Survival after unrelated donor (URD) hematopoietic cell transplantation (HCT) for Acute Myeloid Leukemia (AML) is limited by toxicity and relapse. Killer-cell immunoglobulin-like receptors (KIR) control NK cell alloreactivity after HCT. Hypothesizing that donor KIR genotype (A/A: 2 A KIR haplotypes; B/x: ≥ 1 B haplotype) would affect outcomes, we genotyped donors and recipients from 448 URD transplantations for AML. Three year overall survival was significantly higher after transplantation from a KIR B/x donor (31% [95% CI: 26-36] vs. 20% [95% CI: 13-27]; p = 0.007). Multivariate analysis demonstrated a 30% better relative risk of relapse-free survival with B/x vs. A/A donors (RR 0.70 [95% CI 0.55-0.88]; p=.002). B/x donors were associated with more chronic GVHD (RR 1.51 [95% CI 1.01-2.18]; p=.03), but not more acute GVHD, relapse or treatment-related mortality. This analysis demonstrates that HCT from unrelated donors with KIR B haplotypes confers significant survival benefit for patients with AML.
Description
University of Minnesota M.S. thesis. November 2009. Major: Clinical Research. Advisors: Jeffrey S Miller, MD, Daniel J Weisdorf, MD, Chap T Le, PhD. 1 computer file (PDF); iv, 36 pages, appendix 29-36.
Related to
Replaces
License
Series/Report Number
Funding information
Isbn identifier
Doi identifier
Previously Published Citation
Other identifiers
Suggested citation
Cooley, Sarah Anne. (2009). Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/59769.
Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.